
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
Inpharamo, a subsidiary of Semicrol, has signed a collaboration agreement to support the entry of the Swiss company, Clinerion. The partnership is dedicated to optimizing the identification of patients who are candidates for participation in clinical trials in Mexico.
For more information, click







